SUPPORT LINE

0300 111 1234

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Tolvaptan - 'JINARC' - has been recommended for a license in Europe

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive
 

The European Medicines Agency (EMA) has recommended granting a marketing authorisation to tolvaptan, which now has the brand name: JINARC.

This means that we are very close to seeing the first-ever licensed drug to treat ADPKD on prescription in the UK! A very exciting and historic moment for everyone affected by PKD.

The EU will make the final decision but we assume that will occur soon - and we hope that the approval of JINARC will stimulate more research into treatments for all forms of PKD, in children as well as adults.

JINARC won't be given to everyone with ADPKD. It is indicated to slow down cyst development and failing kidney function in adult patients with normal to moderately reduced kidney function who have rapidly progressing ADPKD.

In the UK, the NHS will carry out a cost-benefit appraisal to decide whether JINARC can be afforded and given on prescription to patients. We have no way of knowing in advance if that decision will be positive. The appraisal meeting is on 1st April and we should hear by August.

Read more about the EMA decision here.Read more about the EMA decision here.

Print Email

0
0
0
s2sdefault

Latest Tweets

PKD Charity is a Member of

  • Fundraising Regulator Website
  • Visit The Information Standard website
  • Visit PKD International website
  • Visit Ciliopathy Alliance website
  • Visit the Genetic Alliance UK website
  • Rare Disease UK Website
  • National Voices Website
  • Specialised Healthcare Alliance Website
  • FEDERG Website
  • Visit EURORDIS website